Use of akkermansia for treating metabolic disorders

Abstract

The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

1 - 17 . (canceled) 
     
     
         18 . A method for treating a metabolic disorder in a subject in need thereof, comprising administering to the subject  Akkermansia muciniphila  or fragments thereof. 
     
     
         19 . The method according to  claim 18 , wherein said metabolic disorder is obesity. 
     
     
         20 . The method according to  claim 18 , wherein said metabolic disorder is selected from the group consisting of metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, Diabetes Mellitus, glucose intolerance, abnormal lipid metabolism, atherosclerosis, hypertension, cardiac pathology, stroke, non-alcoholic fatty liver disease, hyperglycemia, hepatic steatosis, dyslipidemia, dysfunction of the immune system associated with overweight and obesity, cardiovascular diseases, high cholesterol, elevated triglycerides, asthma, sleep apnoea, osteoarthritis, neuro-degeneration, gallbladder disease, syndrome X, inflammatory and immune disorders, atherogenic dyslipidemia and cancer. 
     
     
         21 . The method according to  claim 18 , wherein viable cells of  Akkermansia muciniphila  are administered to the subject in need thereof. 
     
     
         22 . The method according to  claim 18 , wherein  Akkermansia muciniphila  or fragments thereof are orally administered. 
     
     
         23 . The method according to  claim 18 , wherein an amount of  Akkermansia muciniphila  ranging from about 1·10 4  to about 1·10 12  cfu is administered to the subject. 
     
     
         24 . The method according to  claim 18 , wherein  Akkermansia muciniphila  or fragments thereof are administered at least three times a week. 
     
     
         25 . The method according to  claim 18 , wherein  Akkermansia muciniphila  or fragments thereof are co-administered with another probiotic strain and/or with one or more prebiotics. 
     
     
         26 . A method for increasing energy expenditure or for increasing satiety or for promoting weight loss in a subject, comprising administering  Akkermansia muciniphila  or fragments thereof to the subject. 
     
     
         27 . The method according to  claim 26 , wherein said method does not impact the food intake of said subject. 
     
     
         28 . The method according to  claim 26 , wherein viable cells of  Akkermansia muciniphila  are administered to the subject in need thereof. 
     
     
         29 . The method according to  claim 26 , wherein  Akkermansia muciniphila  or fragments thereof are orally administered. 
     
     
         30 . The method according to  claim 26 , wherein an amount of  Akkermansia muciniphila  ranging from about 1·10 4  to about 1·10 12  cfu is administered to the subject. 
     
     
         31 . The method according to  claim 26 , wherein  Akkermansia muciniphila  or fragments thereof are administered at least three times a week. 
     
     
         32 . The method according to  claim 26 , wherein  Akkermansia muciniphila  or fragments thereof are co-administered with another probiotic strain and/or with one or more prebiotics. 
     
     
         33 . A nutritional composition comprising  Akkermansia muciniphila  or fragments thereof.